Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: Pediatr Blood Cancer. 2023 Feb 15;70(5):e30251. doi: 10.1002/pbc.30251

Figure 4. AMkL subgroup Kaplan–Meier curves per trial.

Figure 4.

(A) Event-free survival and (B) overall survival of major AMkL subgroups in trial AAML0531 show statistically significant different survivals depending on the identified fusion, other myelodysplasia-related changes (MRC), or not otherwise specified (NOS). (C) Event-free survival and (D) overall survival of major AMkL subgroups in trial AAML1031 did not show statistically significant different survivals depending on the subcategory.